FeesSafety
Pluang+

Capgemini SE rated Buy with €175 target, promising double-digit returns and stable dividends.

Analyst Insights
27 Oct 2026, 01:11 WIB
Seeking Alpha
View Source
Bullish
Capgemini SE rated Buy with €175 target, promising double-digit returns and stable dividends.

Capgemini SE is rated a Buy with a price target of €175 per share, suggesting significant upside potential. The company has a strong track record of 12-13% annual earnings growth over 20 years, a 2.75% dividend yield, and a solid BBB+ credit rating. Even without major earnings growth, valuation normalization could deliver 20% annualized returns, with limited downside risk unless valuation multiples drop below 7.5x. Key factors to watch include sustainable AI-driven profits, free cash flow recovery, and margin improvements, especially in France, with upcoming Q3 results acting as a catalyst.

Capgemini SE is the subject of this update, with Pluang's Technology-sector market data providing context as of Oct 27, 2026 05:11 WIB. Of 150 priced US Technology stocks on Pluang, 89 rose and 61 fell today. Notable movers include VNET at USD 3.96 with a 6.73% increase, NOK at USD 8.66 up 6.45%, and SNPS at USD 455.64 rising 5.93%.

More News

Presidio named Global Innovation Partner of the Year at Cisco Partner Summit 2026

Presidio named Global Innovation Partner of the Year at Cisco Partner Summit 2026

At the Cisco Partner Summit 2026, Presidio was honored as the Global Innovation Partner of the Year, recognizing its outstanding innovation and success in delivering impactful customer solutions. This award highlights Presidio's commitment to partner...

Market News
Bullish
51 minutes ago
Presidio named Global Services and Software Excellence Partner of the Year at Cisco Partner Summit 2026

Presidio named Global Services and Software Excellence Partner of the Year at Cisco Partner Summit 2026

Presidio was awarded the Global Services and Software Excellence Partner of the Year at the Cisco Partner Summit 2026. This award recognizes Presidio's outstanding innovation and success in delivering solutions that help customers achieve meaningful ...

Market News
Bullish
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
2 hours ago
Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
2 hours ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App